Fate Therapeutics prices IPO at $6, at low end of the revised range

By Renaissance Capital,

Shutterstock photo

Fate Therapeutics, an early clinical-stage biotech developing stem cell treatments for orphan diseases, raised $40 million by offering 6.7 million shares at $6, the low end of the revised range of $6 to $8. The company had initially filed to offer 4.0 million shares at a range of $14 to $16, before cutting the deal size 22% on Monday morning. Fate Therapeutics plans to list on the NASDAQ under the symbol FATE. Cowen & Company and BMO Capital Markets acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: FATE

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com